US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Gilead Sciences Inc (GILD)
Gilead Sciences Inc (GILD) ニュース

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:GILD

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/14	16 : 00	Business Wire	New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment	NASDAQ:GILD	Gilead Sciences Inc
2024/06/12	08 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/06/12	08 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/06/12	08 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/06/12	08 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/06/12	08 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/06/12	08 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/06/06	17 : 30	Business Wire	Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	NASDAQ:GILD	Gilead Sciences Inc
2024/06/05	15 : 00	Business Wire	Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	NASDAQ:GILD	Gilead Sciences Inc
2024/06/03	23 : 00	Business Wire	Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	NASDAQ:GILD	Gilead Sciences Inc
2024/06/03	22 : 00	Business Wire	Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma	NASDAQ:GILD	Gilead Sciences Inc
2024/06/02	21 : 00	Business Wire	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer	NASDAQ:GILD	Gilead Sciences Inc
2024/06/02	21 : 00	Business Wire	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer	NASDAQ:GILD	Gilead Sciences Inc
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NASDAQ:GILD	Gilead Sciences Inc
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NASDAQ:GILD	Gilead Sciences Inc
2024/05/31	21 : 07	Business Wire	EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024	NASDAQ:GILD	Gilead Sciences Inc
2024/05/31	05 : 45	Business Wire	Gilead Provides Update on Phase 3 TROPiCS-04 Study	NASDAQ:GILD	Gilead Sciences Inc
2024/05/22	21 : 30	Business Wire	Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024	NASDAQ:GILD	Gilead Sciences Inc
2024/05/18	21 : 30	Business Wire	Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	NASDAQ:GILD	Gilead Sciences Inc
2024/05/14	23 : 09	Business Wire	Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	06 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	06 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	06 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	06 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	06 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	05 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	05 : 05	Business Wire	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	04 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc
2024/05/10	04 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GILD	Gilead Sciences Inc

Showing the most relevant articles for your search:NASDAQ:GILD

1 2 3 4 5 6 7 8 9 10 次へ >>

Verizon Communications

US Dollar vs Sterling

Bank of America

American Express

US Dollar vs Euro

Energy Select Sector SPDR

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約